Oncolyze is pioneering a novel approach to cancer treatment through its lead investigational drug candidate, OM-301, which targets the human double minute-binding protein-2 (HDM2) found on the surface of cancer cells. This unique mechanism of action allows OM-301 to selectively bind to HDM2, creating pores in the cancer cell membrane, leading to a process termed "pop-tosis." This method of inducing cell death is distinct from traditional apoptosis, as it causes the cancer cells to swell and ultimately burst due to osmotic pressure. The technology has shown promising in vitro efficacy against a variety of cancer cell lines, including those resistant to conventional therapies, while sparing normal cells, which suggests a potentially lower toxicity profile.

In addition to OM-301, Oncolyze is exploring other similar peptides and immune-oncology strategies to enhance therapeutic effectiveness. The company has received orphan drug designation from the FDA for OM-301 in the treatment of acute myeloid leukemia (AML) and is advancing its clinical development. Research collaborations with leading cancer centers and ongoing studies have demonstrated the potential of OM-301 to not only target mature leukemia cells but also leukemia stem cells, which are often responsible for disease relapse. This innovative approach aims to provide new hope for patients with various blood cancers and solid tumors, addressing a significant unmet need in cancer therapy.

United States

Oncolyze is developing therapeutics that exploit a novel mechanism of action for the targeted and selective lysis of cancer cells and cancer stem cells.

Oncolyze

Company Details